Equity Research, Broker Reports, and media content on Aesthetic Medical International Holdings Group Ltd. ADR

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Aesthetic Medical International Holdings Group Ltd. ADR
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Aesthetic Medical International Holdings Group Ltd. ADR

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Aesthetic Medical International Holdings Group Ltd. ADR. We currently have 0 research reports from 0 professional analysts.

  • Open: N/A
  • Range Today: N/A
  • 52 Week: 0.00/0.00
  • Daily Volume: N/A
  • Daily Liquidity: 0.0%
  • # Shares: 0m
  • Market Cap: 0m
  • Latest PE (hist):
  • Div Yield:

Latest News/RNS

(more news)
Date Source Announcement
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Aesthetic Medical International Holdings Group Ltd. ADR

  • Providers covering

    Aesthetic Medical International Holdings Group Ltd. ADR

  • 17 Jun 21
Cenkos: OptiBiotix Health Plc - Final results

OptiBiotix has reported its final results for the year to December 2020, which are largely in-line with the financials reported with the recent ‘Strategy and commercial update'. 2020 was a strong year for the company as its two operational divisions achieved EBITDA profitability supported by increased commercialisation of the group's product range. This commercial moment has continued into 2021, as the company looks to scale its first-generation product sales with new product lines and new terri

Companies: OptiBiotix Health PLC
  • 17 Jun 21
CareTech (CTH) - Interims illustrate earnings growth and operational resilience

CareTech is a specialist social care and educational services provider. This morning, the group has announced interim results to 31 March 2021, which illustrate another positive six month period, particularly when considering the present wider backdrop. An increase in underlying PBT of 31.6% against the prior year benefited from organic growth, as well as the acquisition of Smartbox, transfer in of The Huntercombe Group facilities and a full period contribution from the Middle East. As reported

Companies: CareTech Holdings PLC
  • 01 Jun 21
A Midsummer Day’s Dream…..

As midsummer’s day looms (where has this year gone?), there is greater optimism, in general, than may have been anticipated a few months ago. A post-pandemic, ‘vaccine-driven’ recovery demonstrated by increased consumer spending as lockdown measures are lifted has been one of the catalysts. The FTSE 100 has been range-bound in the last month 6,900-7,100. We have seen a combination of broadly positive company results across a range of sectors, further examples of M&A activity and a sequence of ne

Companies: AMYT ARBB ARW BAG BEG BONH BWNG CWK DNK EML EPWN FBD FA/ GPH GSF GNC HUW IGC INSE KAPE KP2 MMAG NRR NESF OTMP ROL RUA SEN SUR TON TOU TXP TGL VLS WINK

  • 15 Jun 21
Evgen Pharma - FY 2021 results

Evgen reported full-year results to 31 March that were c.£0.3m better than expected, with an adjusted net loss of £2.8m resulting in year-end cash of £11.6m (FC est. £11.3m), which provides a cash runway to at least mid-2023. The company continues to progress SFX-01 in glioma (brain cancer) and metastatic breast cancer (mBC) pre-clinical models, with the aim of commencing a Phase Ib/II trial in Q2 2022 (glioma) and potentially a Phase IIb trial in mBC patients who have become resistant to first-

Companies: Evgen Pharma Plc
  • 16 Jun 21
NetScientific (NSCI) - PDS Biotech participation in placing

Further to yesterday's announcement, NetScientific, the international life sciences and sustainability technology investment and commercialisation group, has announced that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), is to issue c.5.3m new shares of common stock to raise gross proceeds of c.$45m. NetScientific currently owns 1,278,000 shares of PDS' common stock, representing 5.7% of its fully diluted share capital prior to the issue.

Companies: NetScientific plc
  • 01 Apr 21
Recovery rally rolls on in Q1. Outlook for Q2 and beyond?

The UK market showed a continued recovery in the first quarter albeit the indices are still well short of their all-time peaks, unlike many of their international peers. The FTSE 100 has risen by 1,186 points (21.4%) since the end of October and the FTSE 250 by 4,304 points (25.0%). The comparable performance since the start of the year is less spectacular- the FTSE 100 has risen by 253 points (3.9%) and the FTSE 250 has risen by 1,070 points (5.0%). The factors behind the sustained rally are fa

Companies: AMYT ARBB CEG BAG BVC BEG BONH BLVN BRSD CML CWK CRPR EYE ECHO FDM FAR FA/ GPH GSF HUW INSE JDG KAPE KP2 MACF MPAC MNZS NESF NBI OTMP OBD PREM QFI RUA SCS SEN SOS SUR TON TOU TXP TGL TCN UEM VLS WYN

  • 01 Jun 21
2020 final results due

AVO’s goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly derisked the project. Now, AVO is working on the verification and validation phase, prior to LIGHT being used on the first patients to support CE marking. In its recent technical update, the company highlighted progress made over the past three months towards a ful

Companies: AVO ARBB ARIX BBGI CLIG DNL FLTA ICGT OCI PCA PIN RECI STX SPO SCE TRX VTA

  • 11 Jun 21
Positive AGM trading update

Trading has strengthened significantly since restrictions eased in April, especially in the UK. UK brand sales are now up 64% YTD (+18% vs 2019). Further distribution gains are being made, including in the USA and online sales have tripled, albeit off a small base. Net cash has increased to £6.6m (Dec’20, £4.9m). Risk appears to lie to the upside vs prudent forecasts. The re-rating looks well supported to us, and we look forward to the H1 update in July

Companies: Warpaint London PLC
  • 25 May 21
Cenkos: Calnex Solutions plc -- Time (synchronisation) is money

Calnex Solutions has announced record results for FY21 following customer orders up across all product types and within all regions, with FY21 revenue up 31% to £18.0m and adjusted PBT up 43% to £5.1m. Calnex has firmly established a trusted reputation worldwide, launching multiple first to market telecoms and network testing solutions. Calnex continues to accelerate its investment in R&D and expand its product roadmap, adding increased engineering, sales and customer support capacity in order t

Companies: Calnex Solutions Plc
  • 26 May 21
Further upgrade to FY21E estimates

SDI Group has published a second positive trading update ahead of July’s FY21E results announcement. Management’s guidance for revenue and adjusted PBT is approximately £35.3m and £7.4m respectively, ahead of our previous FY21E estimates (and previous guidance) of £34.0m and £6.7m. We upgrade our FY21E forecasts accordingly, with a 10% uplift to our fully adjusted PBT forecast. Current base guidance for FY22E remains unchanged with revenue of £42m and adjusted PBT of £8.7m. Consequently, we are

Companies: SDI Group plc
  • 07 Jun 21
Cenkos: Venture Life Group Plc -- BBI Healthcare acquisition

Venture Life Group has announced the acquisition of BBI Healthcare, a leading Women's Health and Energy Management/Diabetes company. Venture Life will pay up to £36.0m for the business, which generated revenues of £10.2m and adjusted EBITDA of £2.6m in FY20A. We believe the acquisition will fit well within Venture Life, significantly expanding the group's own brand revenues and providing a number of revenue growth and operational leverage opportunities. The acquisition has been financed by exist

Companies: Venture Life Group Plc
  • 09 Jun 21
Major US licence & supply agreement

In an encouraging sign of building US momentum, Yourgene has announced it has signed a multi-year licence and supply agreement with a major US precision medicine company to enable it to offer a new reproductive health screening service from its own laboratories. The agreement encompasses a non-exclusive licence to Yourgene’s proprietary bioinformatics Flex analysis software and a supply agreement for sample preparation reagents and instrumentation. Notably, this includes the Ranger sample enrich

Companies: Yourgene Health Plc
  • 15 Jun 21
NetScientific (NSCI) - PDS Biotech – announced public offering after hours

NetScientific, the international life sciences and sustainability technology investment and commercialisation group, has announced that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has itself announced (after trading hours 14 June) that it is commencing an underwritten public offering of shares of its common stock. PDS intends to use a portion of the net proceeds for the development of its clinical pipeline and the balance for general corporate / working capital purposes.

Companies: NetScientific plc
  • 07 Oct 19
Cancer - Strategy for affordable care

The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc

Companies: VSC ABT ABBV AFMD A GOOGL AMGN AZN BCART BMY EKTAB EXAS GSK ILMN IPH ISRG IBAB JNJ MDXH MDG1 MDT MRK MYGN NSTG NOVN OCX PFE RAYB ROG SAN SGEN TMO TNG VAR VCYT VNRX XNCR ECX IMM

  • 25 Mar 20
Cenkos: Venture Life Group Plc -- Trading update and upgrade

In line with the recent FCA announcement, Venture Life, in conjunction with its auditor has taken the decision to delay the release of its FY19 results, though the company notes it was in position to release them. Also, with this announcement, the group has provided a strong trading update, noting that all business units are still operating as of now. Specifically, Venture Life points to orders of over €7m from its Dentyl partner in China for 2020 (versus €0.5m for 2019), with at least €2m for d

Companies: Venture Life Group Plc